Ritholtz Wealth Management Invests $329,000 in Zymeworks Inc. (NYSE:ZYME)

Ritholtz Wealth Management purchased a new position in Zymeworks Inc. (NYSE:ZYMEFree Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 31,689 shares of the company’s stock, valued at approximately $329,000.

A number of other large investors have also recently made changes to their positions in the stock. Morgan Stanley boosted its holdings in shares of Zymeworks by 6.0% in the fourth quarter. Morgan Stanley now owns 5,573,380 shares of the company’s stock worth $43,807,000 after acquiring an additional 314,405 shares during the period. BlackRock Inc. boosted its holdings in shares of Zymeworks by 371.4% in the second quarter. BlackRock Inc. now owns 3,542,678 shares of the company’s stock worth $30,609,000 after acquiring an additional 2,791,105 shares during the period. Rubric Capital Management LP boosted its holdings in shares of Zymeworks by 12.5% in the third quarter. Rubric Capital Management LP now owns 2,651,394 shares of the company’s stock worth $16,810,000 after acquiring an additional 293,817 shares during the period. Credit Suisse AG boosted its holdings in shares of Zymeworks by 1.0% in the second quarter. Credit Suisse AG now owns 2,509,240 shares of the company’s stock worth $21,680,000 after acquiring an additional 23,955 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Zymeworks by 5.8% in the third quarter. Vanguard Group Inc. now owns 2,383,986 shares of the company’s stock worth $15,114,000 after buying an additional 131,604 shares in the last quarter. 92.89% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider Paul Andrew Moore sold 2,339 shares of the stock in a transaction on Monday, January 8th. The stock was sold at an average price of $11.22, for a total value of $26,243.58. Following the sale, the insider now owns 7,367 shares in the company, valued at $82,657.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Zymeworks news, CEO Kenneth Galbraith sold 18,198 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $10.65, for a total transaction of $193,808.70. Following the sale, the chief executive officer now owns 29,468 shares in the company, valued at $313,834.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Paul Andrew Moore sold 2,339 shares of the firm’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $11.22, for a total value of $26,243.58. Following the sale, the insider now owns 7,367 shares in the company, valued at approximately $82,657.74. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,697 shares of company stock worth $428,174. Corporate insiders own 1.22% of the company’s stock.

Zymeworks Stock Performance

Shares of ZYME stock opened at $9.88 on Tuesday. Zymeworks Inc. has a 52-week low of $6.01 and a 52-week high of $13.14. The company has a market capitalization of $697.21 million, a PE ratio of -5.68 and a beta of 1.16. The business’s fifty day moving average is $11.21 and its 200 day moving average is $9.32.

Zymeworks (NYSE:ZYMEGet Free Report) last issued its quarterly earnings data on Wednesday, March 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.19. Zymeworks had a negative return on equity of 26.20% and a negative net margin of 156.12%. The company had revenue of $16.93 million for the quarter, compared to the consensus estimate of $18.32 million. On average, sell-side analysts forecast that Zymeworks Inc. will post -1.04 EPS for the current fiscal year.

About Zymeworks

(Free Report)

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

Featured Articles

Institutional Ownership by Quarter for Zymeworks (NYSE:ZYME)

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.